Press Releases
OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer
OnKure Therapeutics Appoints Nicholas A. Saccomano, Ph.D., to its Board of Directors
OnKure Therapeutics Announces Positive Topline First-in-Human Phase 1 Results for OKI-179
OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry
OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer
OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer
OnKure Builds its Discovery Team and Appoints Heads of Computational Drug Discovery and Pharmacology
OnKure, Inc. Raises $55 Million Series B Financing
OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib
OnKure Expands Executive Team and Appoints Head of Discovery, Chief Financial Officer and General Counsel
OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor
OnKure Announces FDA IND Regulatory Clearance to Start Phase 1 Trials for OKI-179
OnKure Close $7M Series A Financing to Support Development of Epigenetics Drug